Effectiveness Trial for Evaluating IAHA for PFPS

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 7, 2016

Study Completion Date

March 4, 2017

Conditions
Patellofemoral Pain Syndrome
Interventions
DEVICE

Intra-Articular Hyaluronic Acid-Euflexxa

IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.

Trial Locations (1)

10016

Center for Musculoskeletal Care - NYU Langone Medical Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

NYU Langone Health

OTHER

NCT01811654 - Effectiveness Trial for Evaluating IAHA for PFPS | Biotech Hunter | Biotech Hunter